Detecting HIV-1 seroconverters by a sensitive peptide EIA.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Detecting HIV-1 seroconverters by a sensitive peptide EIA.

Abstr Gen Meet Am Soc Microbiol. 1993;93:434 (abstract no. T-13). Unique Identifier : AIDSLINE ASM93/93291813
Lee-Thomas S; Pau CP; Schochetman G; George JR; Division of HIV/AIDS, Centers for Disease Control and Prevention,; Atlanta.

Abstract: Sixteen overlapping synthetic peptides from the immunodominant region of HIV-1 gp41 (amino acids 581-623) were evaluated in an enzyme immunoassay (EIA) to detect early seroconversion of HIV-1. In addition, two 14 amino-acid peptides, one corresponding to the principle neutralizing domain (V3 region) of HIV-1 gp120, (a.a. 310-323) and the other from the carboxyl-terminal end of gp41, (a.a. 844-857) were also examined. Seventeen commercial seroconversion panels composed of 149 sera serially collected from 17 asymptomatic donors over a period of 17 days to 136 days were examined. The most sensitive peptide was a 23-amino acid peptide P0039 (a.a. 582-604) which detected antibodies in all 17 panels, including 9 panels 7 to 15 days before a commercial whole-viral lysate EIA (Genetic Systems Corporation) and 2 panels that were negative by the commercial EIA. Only one panel was positive by the commercial EIA before becoming positive by the peptide EIA. Therefore, synthetic peptide EIA can be more sensitive than commercial viral-lysate EIA for detecting early seroconverters. A shorter version of P0039 (i.e. immunodominant peptide, a.a. 593-604) was less sensitive than P0039, indicating that a.a. 582-593 are required for the enhanced sensitivity.

Keywords: Human HIV Antibodies/*BLOOD HIV Envelope Protein gp120/IMMUNOLOGY HIV Envelope Protein gp41/IMMUNOLOGY HIV Seropositivity/*DIAGNOSIS HIV-1/*ISOLATION & PURIF Immunoenzyme Techniques Neutralization Tests ABSTRACT
930930
M9391158

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .